Pricing Log in Create free account
Friday 6 November 2026 Export INCY’s income statement to Excel — free account

Incyte Corporation

INCY Healthcare Biotechnology

Incyte Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 21.2% from fiscal 2024.

Revenue
+14.0%
EPS
−277.9%
Free cash flow
−233.0%
Total debt
−10.5%

Quarter to September 2026, against a year earlier

118.62 0.61 +0.52%
Market cap
$24.1B
P/E
56.3×
Fwd P/E
55.6×
Dividend yield
—
F-score
9/9
Altman Z
8.57
Beneish M
−2.43
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Incyte Corporation (INCY) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
10-Q Sep 30, 2026 P1I2: 7 added · 6 removed · 46 modified
P2I1A: 9 modified 		Inventory outpacing revenue
8-K Oct 29, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Aug 31, 2026 8.01 Other events
10-Q Jun 30, 2026 P1I2: 8 added · 4 removed · 34 modified
P2I1A: 4 added · 22 modified
8-K Jul 28, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jul 6, 2026 8.01 Other events; 9.01 Financial statements and exhibits
8-K Jun 22, 2026 8.01 Other events
8-K Jun 8, 2026 5.07 Submission of matters to a vote of security holders
8-K Jun 8, 2026 8.01 Other events
10-Q Mar 31, 2026 P1I2: 32 added · 35 removed · 103 modified
P2I1A: 7 added · 1 removed · 24 modified
8-K Apr 28, 2026 2.02 Results of operations and financial condition
8-K Mar 26, 2026 5.02 Departure or appointment of directors or officers Officer departure
8-K Mar 25, 2026 5.02 Departure or appointment of directors or officers; 9.01 Financial statements and exhibits
8-K Feb 27, 2026 8.01 Other events
10-K Dec 31, 2025 1: 36 added · 94 removed · 76 modified
1A: 4 added · 1 removed · 82 modified
7: 9 added · 8 removed · 36 modified
8-K Feb 10, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Dec 10, 2025 5.02 Departure or appointment of directors or officers
10-Q Sep 30, 2025 P1I2: 17 added · 95 removed · 74 modified
P2I1A: 1 added · 1 removed · 4 modified
8-K Oct 28, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Sep 30, 2025 5.02 Departure or appointment of directors or officers
10-Q Jun 30, 2025 P1I2: 9 added · 6 removed · 31 modified
P2I1A: 1 added · 10 modified
8-K Jul 29, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Mar 31, 2025
8-K Apr 29, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Dec 31, 2024 1: no comparison — no earlier filing on file
1A: no comparison — no earlier filing on file
7: no comparison — no earlier filing on file
8-K Feb 10, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Sep 30, 2024
8-K Oct 29, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2024
8-K Jul 30, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Apr 30, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Feb 13, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.